Germany · Delayed Price · Currency is EUR Noveris Health Sciences Company Description
Noveris Health Sciences Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions.
The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs.
The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds.
Noveris Health Sciences Inc. was formerly known as Mydecine Innovations Group Inc. and changed its name to Noveris Health Sciences Inc. in February 2026.
The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2013 |
| Industry | Agricultural Production Crops |
| CEO | David Bartch |
Contact Details
Address: 1075 West Georgia Street Vancouver, BC V6E 3C9 Canada | |
| Phone | 604 687 2038 |
| Website | mydecine.com |
Stock Details
| Ticker Symbol | 0NF1 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| SIC Code | 0100 |
Key Executives
| Name | Position |
|---|---|
| David Bartch | Chief Executive Officer |
| John Ross | Chief Financial Officer |